OHSU

IRB #

IRB00009902

Title

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Principal Investigator

Matthew Taylor

Study Purpose

To compare the response rate of nivolumab (study drug) alone to the study drug combined with ipilimumab in people with advanced or metastatic solid tumors.

Medical Condition(s)

Triple negative breast cancer (TNBC)
Gastric cancer
Pancreatic cancer
Small cell lung cancer (SCLC)

Eligibility Criteria

1. Men and women age 18 years or older
2. Have measurable disease by CT or MRI
3. Must agree to biopsy from a tumor site that is not the only site of measurable disease
4. Must be willing and able to comply with schedule visits and treatment schedule
5. Other criteria apply

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until disease progression

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Bristol-Myers Squibb (BMS)

Recruitment End

08/31/2014

Compensation Provided

No


Go Back